CU24257B1 - Procedimiento de preparación de 5- fluoro-1h-pirazolopiridinas sustituidas - Google Patents
Procedimiento de preparación de 5- fluoro-1h-pirazolopiridinas sustituidasInfo
- Publication number
- CU24257B1 CU24257B1 CUP2014000055A CU20140055A CU24257B1 CU 24257 B1 CU24257 B1 CU 24257B1 CU P2014000055 A CUP2014000055 A CU P2014000055A CU 20140055 A CU20140055 A CU 20140055A CU 24257 B1 CU24257 B1 CU 24257B1
- Authority
- CU
- Cuba
- Prior art keywords
- fluoro
- formula
- substituted
- medicaments
- pirazolopiridins
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 abstract 5
- 239000003814 drug Substances 0.000 abstract 4
- LTYNYHHABUSSHS-UHFFFAOYSA-N 5-fluoro-1h-pyrazolo[4,3-b]pyridine Chemical class FC1=CC=C2NN=CC2=N1 LTYNYHHABUSSHS-UHFFFAOYSA-N 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/26—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
- C07C303/28—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
- C07C317/04—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/023—Preparation; Separation; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/037—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements with quaternary ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/067—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente solicitud se refiere a un procedimiento novedoso y eficiente para preparar nuevas 5-fluoro-1H- pirazolopiridinas sustituidas de la fórmula (VI) ESPACIO PARA FÓRMULA que son adecuadas como un intermedio para producción de medicamentos y para producción de medicamentos para el tratamiento y/o la profilaxis de trastornos cardiovasculares. Más particularmente, las 5- fluoro- 1H-pirazolopiridinas de la fórmula (VI) son adecuadas para la preparación del compuesto de la fórmula (I) ESPACIO PARA FÓRMULA que sirve para producción de medicamentos, para producción de medicamentos para el tratamiento y/o la profilaxis de trastornos cardiovasculares.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11190789 | 2011-11-25 | ||
| EP11192301 | 2011-12-07 | ||
| PCT/EP2012/073276 WO2013076168A1 (de) | 2011-11-25 | 2012-11-21 | Verfahren zur herstellung von substituierten 5-fluor-1h-pyrazolopyridinen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20140055A7 CU20140055A7 (es) | 2014-10-02 |
| CU24257B1 true CU24257B1 (es) | 2017-05-10 |
Family
ID=47222101
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CUP2015000124A CU24354B1 (es) | 2011-11-25 | 2012-11-21 | Procedimiento de obtención de derivados de tetrafluoropropilmorfolina |
| CUP2014000055A CU24257B1 (es) | 2011-11-25 | 2014-05-21 | Procedimiento de preparación de 5- fluoro-1h-pirazolopiridinas sustituidas |
| CUP2015000123A CU20150123A7 (es) | 2011-11-25 | 2015-09-15 | DOS FORMAS CRISTALINAS DEL COMPUESTO( 4,6-DIAMINO-2-(5-FLUORO-1-(2-FLUOROBENCIL)-1H-PIRAZOLO?(3,4-b)PIRIDIN-3-IL)PIRIMIDIN-5-IL)CARBAMATO DE METILO |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CUP2015000124A CU24354B1 (es) | 2011-11-25 | 2012-11-21 | Procedimiento de obtención de derivados de tetrafluoropropilmorfolina |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CUP2015000123A CU20150123A7 (es) | 2011-11-25 | 2015-09-15 | DOS FORMAS CRISTALINAS DEL COMPUESTO( 4,6-DIAMINO-2-(5-FLUORO-1-(2-FLUOROBENCIL)-1H-PIRAZOLO?(3,4-b)PIRIDIN-3-IL)PIRIMIDIN-5-IL)CARBAMATO DE METILO |
Country Status (41)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| DE102010043380A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Benzyl-substituierte Carbamate und ihre Verwendung |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| EA031602B1 (ru) | 2011-11-25 | 2019-01-31 | Адверио Фарма Гмбх | Способы получения альдегидов |
| HK1217488A1 (zh) | 2013-02-21 | 2017-01-13 | Adverio Pharma Gmbh | {4,6-二氨基-2-[1-(2-氟苄基)-1h-吡唑并[3,4-b]吡啶-3-基]嘧啶-5-基}甲基氨基甲酸甲酯的形式 |
| TWI639607B (zh) | 2013-06-18 | 2018-11-01 | 美國禮來大藥廠 | Ｂａｃｅ抑制劑 |
| EA201891416A1 (ru) | 2015-12-14 | 2018-12-28 | Айронвуд Фармасьютикалз, Инк. | ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ ДИСФУНКЦИИ ЖЕЛУДОЧНО-КИШЕЧНОГО СФИНКТЕРА |
| US20190381039A1 (en) | 2016-12-13 | 2019-12-19 | Cyclerion Therapeutics, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS |
| JP7090639B2 (ja) | 2017-04-11 | 2022-06-24 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | フッ素置換されたインダゾール化合物及びその使用 |
| US12220414B2 (en) | 2018-07-11 | 2025-02-11 | Tisento Therapeutics Inc. | Use of sGC stimulators for the treatment of mitochondrial disorders |
| TWI830835B (zh) * | 2018-12-17 | 2024-02-01 | 德商亞德維瑞醫藥有限公司 | 具改善性質之{4,6-二胺基-2-[5-氟-1-(2-氟芐基)-1H-吡唑並[3,4-b]吡啶-3-基]嘧啶-5-基}胺基甲酸甲酯活性化合物產物、其製造及調配物 |
| JP7471306B2 (ja) * | 2019-01-22 | 2024-04-19 | アドヴェリオ・ファーマ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ４－（２，２，３，３－テトラフルオロプロピル）モルホリンを製造する方法 |
| JP7780442B2 (ja) * | 2020-02-03 | 2025-12-04 | アドヴェリオ・ファーマ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | メチル｛４，６－ジアミノ－２－［５－フルオロ－１－（２－フルオロベンジル）－１Ｈ－ピラゾロ［３，４－ｂ］ピリジン－３－イル］ピリミジン－５－イル｝カルバメートのナノ製剤 |
| EP3925953A1 (en) | 2020-06-16 | 2021-12-22 | Adverio Pharma GmbH | Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate |
| WO2023034364A1 (en) | 2021-08-31 | 2023-03-09 | Teva Pharmaceuticals International Gmbh | Solid state forms of vericiguat and process for preparation thereof |
| ES2956054B2 (es) | 2022-05-03 | 2024-07-01 | Moehs Iberica Sl | 2-(5-FLUORO-1-(2-FLUOROBENCIL)-1H-PIRAZOLO[3,4-b]PIRIDIN-3-IL)-5-NITROSOPIRIMIDIN-4,6-DIAMINA O UNA SAL DE LA MISMA, PROCEDIMIENTO PARA SU PREPARACION Y SU USO EN LA SINTESIS DE VERICIGUAT |
| CN115043835B (zh) * | 2022-06-17 | 2023-05-09 | 常州制药厂有限公司 | 一种维立西呱的精制纯化方法 |
| WO2024038398A1 (en) * | 2022-08-18 | 2024-02-22 | Torrent Pharmaceuticals Limited | Novel salt of substituted 5-fluoro-1h-pyrazolopyridines and its uses |
| WO2025114276A1 (en) | 2023-12-01 | 2025-06-05 | Krka, D.D., Novo Mesto | Solid oral composition comprising vericiguat |
| US20250205235A1 (en) | 2023-12-20 | 2025-06-26 | Adverio Pharma Gmbh | Dose regimen for vericiguat |
| CN117924280B (zh) * | 2024-03-20 | 2024-07-12 | 中国人民解放军军事科学院军事医学研究院 | 取代噻吩基-5-氟-1h-吡唑并吡啶类化合物及其用途 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8606936D0 (en) * | 1986-03-20 | 1986-04-23 | Ici Plc | Organic compounds |
| GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| DE19642255A1 (de) | 1996-10-14 | 1998-04-16 | Bayer Ag | Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten |
| ES2325045T3 (es) | 1996-10-14 | 2009-08-24 | Bayer Healthcare Ag | Nuevos derivados de pirazol heterociclilmetil sustituidos y su uso en el tratamiento de enfermedades cardiovasculares. |
| US6451805B1 (en) | 1997-11-14 | 2002-09-17 | Bayer Aktiengesellschaft | Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834045A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin |
| DE19846514A1 (de) | 1998-10-09 | 2000-04-20 | Bayer Ag | Neue Heterocyclyl-methyl-substituierte Pyrazole |
| ID28945A (id) | 1998-11-16 | 2001-07-19 | Basf Ag | Turunan-turunan 3-(benzalol-7-il)-ih-pirimidin-2,4-dion |
| DE19920352A1 (de) | 1999-05-04 | 2000-11-09 | Bayer Ag | Substituiertes Pyrazolderivat |
| WO2002042299A1 (de) | 2000-11-22 | 2002-05-30 | Bayer Aktiengesellschaft | Neue lactam-substituierte pyrazolopyridinderivate |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10057754A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Sulfonamid-substituierte Pyrazolopyridinderivate |
| DE10131987A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Pyridin-substituierte Pyrazolopyridinderivate |
| DE10057751A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Carbamat-substituierte Pyrazolopyridinderivate |
| DE10122894A1 (de) | 2001-05-11 | 2002-11-14 | Bayer Ag | Neue Sulfonat-substituierte Pyrazolopyridinderivate |
| IL159238A0 (en) | 2001-06-22 | 2004-06-01 | Boehringer Ingelheim Pharma | Crystalline anticholinergic, method for its production, and use thereof in the production of a drug |
| DE10132416A1 (de) | 2001-07-04 | 2003-01-16 | Bayer Ag | Neue Morpholin-überbrückte Pyrazolopyridinderivate |
| DE10153737A1 (de) | 2001-10-31 | 2003-05-28 | Boehringer Ingelheim Pharma | Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels |
| DE10220570A1 (de) * | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| DE10222550A1 (de) | 2002-05-17 | 2003-11-27 | Bayer Ag | Substituierte Benzyl-pyrazolopyridine |
| DE10232572A1 (de) | 2002-07-18 | 2004-02-05 | Bayer Ag | Neue 2,5-disubstituierte Pyrimidinderivate |
| DE10232571A1 (de) | 2002-07-18 | 2004-02-05 | Bayer Ag | 4-Aminosubstituierte Pyrimidinderivate |
| DE10351903A1 (de) | 2003-11-06 | 2005-06-09 | Bayer Healthcare Ag | Neue Kombination |
| DE102006021733A1 (de) * | 2006-05-09 | 2007-11-22 | Bayer Healthcare Ag | 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung |
| DE102006031175A1 (de) | 2006-07-06 | 2008-01-10 | Bayer Healthcare Ag | Wässrige Arzneimittelformulierung von 4-[((4-Carboxybutyl)-(2[(4-phenethyl-benzyl)oxy]-phenethyl)amino)methyl]benzoesäur |
| DE102006043443A1 (de) | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
| WO2009000832A2 (en) | 2007-06-25 | 2008-12-31 | Boehringer Ingelheim International Gmbh | Chemical compounds |
| AR067762A1 (es) | 2007-07-31 | 2009-10-21 | Vertex Pharma | Proceso para preparar 5-fluoro-1h-pirazolo (3,4-b) piridin-3-amina y derivados de la misma |
| WO2009145814A2 (en) | 2008-03-10 | 2009-12-03 | Vertex Pharmaceuticals Incorporated | Pyrimidines and pyridines useful as inhibitors of protein kinases |
| KR100979460B1 (ko) * | 2008-05-13 | 2010-09-02 | 한국과학기술연구원 | 함불소알킬그룹이 치환된 이온성 액체의 직접 제조방법 |
| DE102009004245A1 (de) | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung |
| UY33041A (es) * | 2009-11-27 | 2011-06-30 | Bayer Schering Pharma Aktienegesellschaft | Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico |
| UY33040A (es) * | 2009-11-27 | 2011-06-30 | Bayer Schering Pahrma Akitengesellschaft | Nuevas formas polimorfas de {4,6diamino-2-[1-(2-fluorobencil-1h-pirazol[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo |
| ES2553035T3 (es) | 2009-11-27 | 2015-12-03 | Adverio Pharma Gmbh | Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1H-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}-metilcarbamato de metilo y su purificación para el uso como principio activo farmacéutico |
| WO2011115804A1 (en) | 2010-03-17 | 2011-09-22 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| DE102010021637A1 (de) * | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| JP6114189B2 (ja) | 2010-07-09 | 2017-04-12 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 縮合ピリミジンおよびトリアジンならびに心血管障害の処置および／または予防のためのその使用 |
| DE102010040234A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Verfahren zur Herstellung von 5-Flour-1H-pyrazolo[3,4-b]pyridin-3-carbonitril |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| DE102010043380A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Benzyl-substituierte Carbamate und ihre Verwendung |
| DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
| EP2751106B1 (de) | 2011-09-02 | 2017-10-18 | Bayer Intellectual Property GmbH | Substituierte annellierte pyrimidine und ihre verwendung |
| EA031602B1 (ru) * | 2011-11-25 | 2019-01-31 | Адверио Фарма Гмбх | Способы получения альдегидов |
-
2012
- 2012-11-21 EA EA201690521A patent/EA031602B1/ru not_active IP Right Cessation
- 2012-11-21 SG SG11201402111QA patent/SG11201402111QA/en unknown
- 2012-11-21 UA UAA201406974A patent/UA116623C2/uk unknown
- 2012-11-21 SG SG10201604192XA patent/SG10201604192XA/en unknown
- 2012-11-21 PT PT151515939T patent/PT2896617T/pt unknown
- 2012-11-21 EP EP18178621.1A patent/EP3421470B8/de active Active
- 2012-11-21 MY MYPI2018001783A patent/MY197904A/en unknown
- 2012-11-21 DK DK15151593.9T patent/DK2896617T3/en active
- 2012-11-21 LT LTEP12790891.1T patent/LT2782914T/lt unknown
- 2012-11-21 CU CUP2015000124A patent/CU24354B1/es unknown
- 2012-11-21 ES ES18178621T patent/ES2864009T3/es active Active
- 2012-11-21 CR CR20210072A patent/CR20210072A/es unknown
- 2012-11-21 CR CR20190057A patent/CR20190057A/es unknown
- 2012-11-21 KR KR1020197003426A patent/KR102026059B1/ko active Active
- 2012-11-21 EP EP15151593.9A patent/EP2896617B1/de active Active
- 2012-11-21 HR HRP20181818TT patent/HRP20181818T1/hr unknown
- 2012-11-21 LT LTEP15151593.9T patent/LT2896617T/lt unknown
- 2012-11-21 LT LTEP18178621.1T patent/LT3421470T/lt unknown
- 2012-11-21 EA EA201690520A patent/EA033455B1/ru not_active IP Right Cessation
- 2012-11-21 MX MX2017014201A patent/MX375872B/es unknown
- 2012-11-21 RS RS20210372A patent/RS61609B1/sr unknown
- 2012-11-21 HU HUE12790891A patent/HUE041592T2/hu unknown
- 2012-11-21 SI SI201230770A patent/SI2896617T1/sl unknown
- 2012-11-21 WO PCT/EP2012/073276 patent/WO2013076168A1/de not_active Ceased
- 2012-11-21 MX MX2014006018A patent/MX357481B/es active IP Right Grant
- 2012-11-21 CA CA2856706A patent/CA2856706C/en active Active
- 2012-11-21 PL PL18178621T patent/PL3421470T3/pl unknown
- 2012-11-21 PT PT12790891T patent/PT2782914T/pt unknown
- 2012-11-21 CN CN201610014399.8A patent/CN105503867B/zh active Active
- 2012-11-21 HU HUE15151593A patent/HUE031029T2/en unknown
- 2012-11-21 PE PE2018003204A patent/PE20190180A1/es unknown
- 2012-11-21 HU HUE18178621A patent/HUE053745T2/hu unknown
- 2012-11-21 BR BR122020001312-5A patent/BR122020001312B1/pt active IP Right Grant
- 2012-11-21 SG SG10201604196VA patent/SG10201604196VA/en unknown
- 2012-11-21 CN CN201611138520.4A patent/CN106905314A/zh active Pending
- 2012-11-21 ES ES12790891.1T patent/ES2694158T3/es active Active
- 2012-11-21 SI SI201231439T patent/SI2782914T1/sl unknown
- 2012-11-21 PL PL12790891T patent/PL2782914T3/pl unknown
- 2012-11-21 MY MYPI2014701335A patent/MY168412A/en unknown
- 2012-11-21 UA UAA201703940A patent/UA119269C2/uk unknown
- 2012-11-21 CN CN201280066381.2A patent/CN104159898B/zh active Active
- 2012-11-21 BR BR112014012414-0A patent/BR112014012414B1/pt active IP Right Grant
- 2012-11-21 EP EP12790891.1A patent/EP2782914B1/de active Active
- 2012-11-21 JP JP2014542816A patent/JP6189315B2/ja active Active
- 2012-11-21 UA UAA201703936A patent/UA120278C2/uk unknown
- 2012-11-21 PE PE2014000713A patent/PE20142359A1/es active IP Right Grant
- 2012-11-21 EA EA201892050A patent/EA201892050A1/ru unknown
- 2012-11-21 AP AP2014007705A patent/AP2014007705A0/xx unknown
- 2012-11-21 PL PL15151593T patent/PL2896617T3/pl unknown
- 2012-11-21 KR KR1020177033016A patent/KR101943788B1/ko active Active
- 2012-11-21 RS RS20181317A patent/RS57945B1/sr unknown
- 2012-11-21 KR KR1020147017000A patent/KR101993022B1/ko active Active
- 2012-11-21 PT PT181786211T patent/PT3421470T/pt unknown
- 2012-11-21 RS RS20161004A patent/RS55387B1/sr unknown
- 2012-11-21 CA CA3040720A patent/CA3040720C/en active Active
- 2012-11-21 DK DK18178621.1T patent/DK3421470T3/da active
- 2012-11-21 DK DK12790891.1T patent/DK2782914T3/en active
- 2012-11-21 AP AP2015008243A patent/AP3898A/en active
- 2012-11-21 PE PE2018003205A patent/PE20190181A1/es unknown
- 2012-11-21 ES ES15151593.9T patent/ES2603028T3/es active Active
- 2012-11-21 EA EA201491028A patent/EA030018B1/ru not_active IP Right Cessation
- 2012-11-21 AU AU2012342547A patent/AU2012342547C1/en active Active
- 2012-11-21 SI SI201231895T patent/SI3421470T1/sl unknown
- 2012-11-21 MY MYPI2018001784A patent/MY198086A/en unknown
- 2012-11-21 TR TR2018/16203T patent/TR201816203T4/tr unknown
- 2012-11-22 JO JOP/2012/0351A patent/JOP20120351B1/ar active
- 2012-11-23 AR ARP120104425A patent/AR088983A1/es active IP Right Grant
- 2012-11-23 TW TW105136776A patent/TWI631123B/zh active
- 2012-11-23 TW TW101143843A patent/TWI597280B/zh active
- 2012-11-23 TW TW108113331A patent/TW201932465A/zh unknown
- 2012-11-23 UY UY0001034467A patent/UY34467A/es unknown
- 2012-11-23 TW TW107124021A patent/TWI665198B/zh active
- 2012-11-23 TW TW107115179A patent/TWI659016B/zh active
- 2012-11-26 US US13/684,670 patent/US8802847B2/en active Active
-
2014
- 2014-05-13 IL IL232585A patent/IL232585A0/en active IP Right Grant
- 2014-05-19 ZA ZA2014/03613A patent/ZA201403613B/en unknown
- 2014-05-21 DO DO2014000112A patent/DOP2014000112A/es unknown
- 2014-05-21 CR CR20140237A patent/CR20140237A/es unknown
- 2014-05-21 CU CUP2014000055A patent/CU24257B1/es unknown
- 2014-05-22 EC ECIEPI20141627A patent/ECSP14001627A/es unknown
- 2014-05-22 CL CL2014001339A patent/CL2014001339A1/es unknown
- 2014-05-22 PH PH12014501160A patent/PH12014501160B1/en unknown
- 2014-05-23 CO CO14111814A patent/CO6960555A2/es unknown
- 2014-05-23 GT GT201400101A patent/GT201400101A/es unknown
- 2014-07-01 US US14/320,875 patent/US9150573B2/en active Active
-
2015
- 2015-06-29 PH PH12015501494A patent/PH12015501494B1/en unknown
- 2015-07-10 US US14/796,703 patent/US9604948B2/en active Active
- 2015-08-18 ZA ZA2015/05970A patent/ZA201505970B/en unknown
- 2015-09-15 CU CUP2015000123A patent/CU20150123A7/es unknown
-
2016
- 2016-02-12 CL CL2016000344A patent/CL2016000344A1/es unknown
- 2016-06-16 IL IL246265A patent/IL246265B/en active IP Right Grant
- 2016-09-20 JP JP2016182821A patent/JP6340391B2/ja active Active
- 2016-11-14 HR HRP20161501TT patent/HRP20161501T1/hr unknown
-
2017
- 2017-01-16 DO DO2017000013A patent/DOP2017000013A/es unknown
- 2017-02-17 US US15/435,964 patent/US9845300B2/en active Active
- 2017-11-02 AU AU2017254916A patent/AU2017254916B2/en active Active
- 2017-11-13 JP JP2017218037A patent/JP6392436B2/ja active Active
- 2017-11-14 US US15/812,524 patent/US10364229B2/en active Active
-
2018
- 2018-08-22 JP JP2018155294A patent/JP2018199698A/ja active Pending
- 2018-11-29 IL IL263389A patent/IL263389B/en unknown
-
2019
- 2019-02-19 US US16/278,813 patent/US10633357B2/en active Active
- 2019-02-19 US US16/278,778 patent/US10633356B2/en active Active
- 2019-03-27 AU AU2019202123A patent/AU2019202123B2/en active Active
-
2021
- 2021-03-26 CY CY20211100270T patent/CY1124000T1/el unknown
- 2021-03-30 HR HRP20210507TT patent/HRP20210507T1/hr unknown
- 2021-04-05 JO JOP/2021/0064A patent/JOP20210064A1/ar unknown
- 2021-04-05 JO JOP/2021/0065A patent/JOP20210065A1/ar unknown
- 2021-08-25 DO DO2021000179A patent/DOP2021000179A/es unknown
-
2022
- 2022-02-24 UY UY0001039646A patent/UY39646A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2021000179A (es) | Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas | |
| CO6771439A2 (es) | Inhibidores de benzodioxano de la producción de leucotrieno | |
| MX2020010330A (es) | Proceso para preparar un compuesto antiviral de formula i. | |
| CR20160119A (es) | Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística | |
| CU24263B1 (es) | Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer | |
| CO7310531A2 (es) | 4-metil-2,3,8,9,9b-pentaaza-ciclopenta [a] naftalenos | |
| ECSP13012494A (es) | Inhibidores de oxadiazol de la producción de leucotrieno. | |
| BR112014026053A2 (pt) | método de preparo de para-xileno a partir de biomassa | |
| BR112014014939A2 (pt) | composição de tratamento de sementes | |
| BR112015023343A2 (pt) | método para preparar sovaprevir, método de preparar um composto da fórmula (c), método de preparação do composto f-2, composto, processo, método de preparação de uma forma amorfa pura de sovaprevir, e,forma cristalina de sovaprevir | |
| MX385406B (es) | Formulación de biomasa. | |
| MX2020009462A (es) | Procesos para la preparación de compuestos de pirimidinilciclopentano. | |
| BR112018074287A2 (pt) | processo para preparação de eribulina e intermediários da mesma | |
| BR112015014440A2 (pt) | processo para a produção de uma solução aquosa purificada de peróxido de hidrogênio | |
| CL2017002148A1 (es) | Derivados de tetrahidropiranil benzamida | |
| BR112017008663A2 (pt) | método para a produção de álcool | |
| TN2014000227A1 (en) | Method for producing substituted 5-fluoro-1h-pyrazolopyridines | |
| CL2015002668A1 (es) | Procesos e intermedios para prepara unmedicamento |